Anmol Baranwal

438 total citations
24 papers, 196 citations indexed

About

Anmol Baranwal is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Anmol Baranwal has authored 24 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 10 papers in Genetics and 5 papers in Oncology. Recurrent topics in Anmol Baranwal's work include Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Anmol Baranwal is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Anmol Baranwal collaborates with scholars based in United States and Australia. Anmol Baranwal's co-authors include Anne Dilley, Connie H. Miller, Claire S. Philipp, Rachel Schwartz, Bruce L. Evatt, Gloria Bachmann, P. Saidi, Mithun Vinod Shah, Devendra Hiwase and Mohamed A. Kharfan‐Dabaja and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Anmol Baranwal

18 papers receiving 188 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anmol Baranwal United States 6 130 65 54 29 26 24 196
Peter V. Pickens United States 6 76 0.6× 39 0.6× 16 0.3× 38 1.3× 11 0.4× 13 148
Ramya Varadarajan United States 5 54 0.4× 21 0.3× 31 0.6× 17 0.6× 57 2.2× 12 148
Ulises Zanetto United Kingdom 6 32 0.2× 58 0.9× 11 0.2× 6 0.2× 31 1.2× 15 151
Shawn Kalloway United States 4 210 1.6× 34 0.5× 162 3.0× 11 0.4× 3 0.1× 5 301
Angela Melpignano Italy 9 289 2.2× 253 3.9× 13 0.2× 2 0.1× 33 1.3× 24 358
Nadia Raban France 7 32 0.2× 5 0.1× 20 0.4× 47 1.6× 62 2.4× 17 145
Po-Nan Wang Taiwan 6 19 0.1× 12 0.2× 5 0.1× 67 2.3× 26 1.0× 10 126
Ana Catalina Kempfer Argentina 9 232 1.8× 100 1.5× 25 0.5× 1 0.0× 2 0.1× 28 295
Morgan Haines Australia 6 87 0.7× 54 0.8× 5 0.1× 1 0.0× 46 1.8× 11 177
Arnaud Lesegretain United States 6 69 0.5× 22 0.3× 2 0.0× 3 0.1× 45 1.7× 20 169

Countries citing papers authored by Anmol Baranwal

Since Specialization
Citations

This map shows the geographic impact of Anmol Baranwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anmol Baranwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anmol Baranwal more than expected).

Fields of papers citing papers by Anmol Baranwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anmol Baranwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anmol Baranwal. The network helps show where Anmol Baranwal may publish in the future.

Co-authorship network of co-authors of Anmol Baranwal

This figure shows the co-authorship network connecting the top 25 collaborators of Anmol Baranwal. A scholar is included among the top collaborators of Anmol Baranwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anmol Baranwal. Anmol Baranwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Baranwal, Anmol, Mehrdad Hefazi, Abhishek A. Mangaonkar, et al.. (2024). Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis. Transplantation and Cellular Therapy. 30(2). S264–S265.
3.
Baranwal, Anmol, Mark E. Gurney, Aref Al‐Kali, et al.. (2024). The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Advances. 8(12). 3130–3139. 5 indexed citations
4.
Baranwal, Anmol, Abhishek A. Mangaonkar, Mehrdad Hefazi, et al.. (2024). Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis. Blood. 144(Supplement 1). 4918–4918.
5.
Baranwal, Anmol, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, et al.. (2024). Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. 31(1). 16.e1–16.e9.
6.
Gurney, Mark E., Anmol Baranwal, Allison Rosenthal, et al.. (2024). Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. JAMA Oncology. 10(4). 532–532. 17 indexed citations
7.
Baranwal, Anmol, Rong He, David S. Viswanatha, et al.. (2023). Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Advances. 8(3). 562–570. 1 indexed citations
8.
Baranwal, Anmol, Rakchha Chhetri, David T Yeung, et al.. (2023). Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplantation. 58(7). 769–776. 5 indexed citations
9.
Gurney, Mark E., Anmol Baranwal, Patricia T. Greipp, et al.. (2023). The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British Journal of Haematology. 202(2). 279–283. 4 indexed citations
10.
Baranwal, Anmol, Isla McKerrow Johnson, Mohamed A. Kharfan‐Dabaja, et al.. (2023). Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(6). 360.e1–360.e8. 2 indexed citations
11.
Baranwal, Anmol, Khaled Ali, Mohamed A. Kharfan‐Dabaja, et al.. (2023). Surrogates of Endothelial Injury Predict Non-Relapse Mortality Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy. 29(2). S9–S10. 1 indexed citations
12.
Baranwal, Anmol, Rakchha Chhetri, Chung Hoow Kok, et al.. (2022). Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms. Transplantation and Cellular Therapy. 28(3). S137–S138. 2 indexed citations
13.
Baranwal, Anmol, Aref Al‐Kali, James M. Foran, et al.. (2022). Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies. Transplantation and Cellular Therapy. 28(3). S126–S127. 1 indexed citations
14.
Shah, Mithun Vinod, Rakchha Chhetri, Chung Hoow Kok, et al.. (2022). Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms. American Journal of Hematology. 97(8). 1013–1022. 8 indexed citations
15.
Baranwal, Anmol, Christopher N Hahn, Mithun Vinod Shah, & Devendra Hiwase. (2022). Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. Current Hematologic Malignancy Reports. 17(6). 254–265. 13 indexed citations
16.
Baranwal, Anmol, Mithun Vinod Shah, David S. Viswanatha, et al.. (2022). Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms. Blood. 140(Supplement 1). 3235–3236. 1 indexed citations
17.
18.
Desai, Parth, et al.. (2020). Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma. Journal of Investigative Medicine High Impact Case Reports. 8. 2737398579–2737398579. 2 indexed citations
19.
Schroeder, M., et al.. (2019). ABSTRACTS OF THE 7TH INTERNATIONAL CONFERENCE ON ADVANCES IN HEMATOLOGY AND ONCOLOGY (ICAHO2019). Anticancer Research. 39(10). 5841–5851.
20.
Philipp, Claire S., Anne Dilley, Connie H. Miller, et al.. (2003). Platelet functional defects in women with unexplained menorrhagia. Journal of Thrombosis and Haemostasis. 1(3). 477–484. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter V. Pickens Breakdown of academic impact, for papers by Ramya Varadarajan Breakdown of academic impact, for papers by Ulises Zanetto Breakdown of academic impact, for papers by Shawn Kalloway Breakdown of academic impact, for papers by Angela Melpignano Breakdown of academic impact, for papers by Nadia Raban Breakdown of academic impact, for papers by Po-Nan Wang Breakdown of academic impact, for papers by Ana Catalina Kempfer Breakdown of academic impact, for papers by Morgan Haines Breakdown of academic impact, for papers by Arnaud Lesegretain
Rankless by CCL
2026